FuMetric Technologies

FuMetric Technologies is a digital health company focused on AI-driven solutions for cardiac care, though specific founding details and headquarters location remain undisclosed in available sources.

Reviewed by 7wData
Share Email

On this page

Profile

Develops AI-powered cardiac monitoring and diagnostic tools to improve patient outcomes.

FuMetric Technologies is a digital health company focused on AI-driven solutions for cardiac care, though specific founding details and headquarters location remain undisclosed in available sources. The company's financial trajectory shows significant growth, with Q1 2026 revenue reaching $199.4 million, a 25.7% increase year-over-year, and gross margins improving to 70.9%. This performance is driven by demand for its Zio® ambulatory ECG portfolio, which serves cardiology, primary care, and international markets.

Recent operational highlights include partnerships with major healthcare providers and the launch of a digital education platform to expand its reach. The company has $549.6 million in unrestricted cash and raised its 2026 revenue guidance to $875-$885 million, signaling confidence in continued expansion. FuMetric's pivot toward AI-enabled capabilities for early disease detection positions it in a competitive but rapidly evolving digital health landscape.

Track FuMetric Technologies and 240+ vendors.

335k+ subscribers read the daily AI & data note. One email, both newsletters. Unsubscribe anytime.

Who buys this

  • Cardiology clinics and hospitals
  • Primary care providers
  • International healthcare systems
  • Employer-sponsored wellness programs
  • Clinical research organizations

Strengths and what to watch

Strengths

  • Strong revenue growth (25.7% YoY in Q1 2026) with improving margins
  • $549.6 million cash position provides runway for expansion
  • Diversified adoption across cardiology, primary care, and international markets

Watch for

  • Dependence on Zio product line for majority of revenue
  • Regulatory risks in expanding AI diagnostic claims
  • Increasing competition in digital cardiac monitoring space

Key Information

Founded
2011
Headquarters
Alpharetta, Georgia, United States

Frequently Asked Questions

What does FuMetric Technologies do?

FuMetric develops AI-powered cardiac monitoring tools, primarily its Zio® ambulatory ECG system, to improve heart disease detection. The company serves cardiologists, primary care providers, and international healthcare systems with diagnostic solutions that combine wearable tech with AI analytics for better patient outcomes. (42 words)

How is FuMetric Technologies performing financially?

FuMetric reported $199.4M Q1 2026 revenue, a 25.7% year-over-year increase, with gross margins reaching 70.9%. The company holds $549.6M in unrestricted cash and raised its 2026 revenue guidance to $875-$885M, reflecting strong demand for its cardiac monitoring products. (45 words)

What is FuMetric's Zio ECG system?

The Zio® portfolio includes wearable ECG monitors that record heart activity continuously. These AI-enabled devices help detect arrhythmias and other cardiac issues, serving cardiology clinics, primary care providers, and international markets through partnerships with major healthcare organizations. (42 words)

Who uses FuMetric's cardiac monitoring technology?

Key customers include cardiology clinics, hospitals, primary care providers, and international healthcare systems. The technology also serves employer wellness programs and clinical research organizations, demonstrating broad adoption across different healthcare segments. (40 words)

How does FuMetric use AI in cardiac care?

FuMetric integrates AI algorithms with its wearable ECG devices to enhance early disease detection. The technology analyzes heart rhythm patterns to identify abnormalities, aiming to improve diagnostic accuracy while reducing manual review time for healthcare providers. (43 words)

What are the risks for FuMetric Technologies?

Key challenges include reliance on the Zio product line for most revenue, regulatory hurdles for AI diagnostics, and growing competition in digital cardiac monitoring. However, strong cash reserves and diversified market adoption help mitigate these risks. (44 words)

Sources

  1. investors.irhythmtech.com — Q1 2026 financial results and operational highlights
  2. www.newsfilecorp.com — Comparative financial performance metrics
  3. techcrunch.com — Industry context on 2025 tech sector challenges
  4. www.informationweek.com — Broader tech industry trends affecting growth companies